rethinkTHC Search
Menu
Study breakdown

Review: Cannabinoids Show Anti-Inflammatory Potential Across Alzheimer's, Parkinson's, ALS, and MS

Narrative ReviewLow evidence
The takeaway

A review found cannabinoids have significant therapeutic potential for neurodegenerative and neuroinflammatory diseases due to their dual ability to modulate both neural and immune functions across multiple pathological mechanisms.

neurologists, neuroimmunologists, patients with neurodegenerative conditions, cannabis researchers

What the researchers found

Cannabinoids show anti-inflammatory therapeutic potential across Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and HIV-associated dementia. Their broad spectrum of action allows targeting multiple pathological mechanisms simultaneously, including neuroinflammation, oxidative stress, and immune dysregulation.

Why it matters

Neurodegenerative diseases and CNS inflammatory conditions share overlapping immune-mediated pathology. Cannabinoids unique ability to simultaneously modulate both neural and immune functions positions them as potential multi-target therapeutics for conditions where single-mechanism drugs have failed.

The numbers in context

Conditions reviewed: Alzheimer's, Parkinson's, ALS, Huntington's, multiple sclerosis, HIV-associated dementia. Mechanisms: neuroinflammation, immune modulation, neuroprotection, oxidative stress reduction.

How the study worked

Narrative review of cannabinoid anti-inflammatory properties across neurodegenerative and CNS inflammatory conditions. Focused on preclinical and clinical evidence for each condition.

What this study cannot tell us

Narrative review without systematic methodology. Much evidence is preclinical. Clinical trial data for cannabinoids in most neurodegenerative diseases is limited. Anti-inflammatory effects may not translate to disease modification in humans.

How to read the evidence

Comprehensive narrative review spanning multiple conditions, but largely preclinical evidence with limited clinical trial data for most conditions.

When this study was published

2025 publication.

The bigger picture

The failure of single-target drugs for neurodegenerative diseases has driven interest in multi-target approaches. Cannabinoids naturally engage multiple protective mechanisms, making them attractive candidates for conditions where neuroinflammation drives disease progression.

Questions still open

  • Which cannabinoid formulations are most promising for each neurodegenerative condition?
  • Can cannabinoid anti-inflammatory effects modify disease progression or only manage symptoms?

Common questions

Can cannabinoids help with neurodegenerative diseases?
This review found cannabinoids have anti-inflammatory properties relevant to Alzheimer's, Parkinson's, ALS, Huntington's, MS, and HIV-associated dementia. Their ability to modulate both neural and immune functions simultaneously makes them promising candidates, though most evidence is still preclinical.
How do cannabinoids protect the brain?
Cannabinoids can reduce neuroinflammation, modulate immune responses, and protect neurons from oxidative stress. This review found these multi-target properties may be particularly valuable for neurodegenerative diseases where single-mechanism drugs have failed.

Read the original research

Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS.

International journal of molecular sciences, 26(14)

Citation

Tomaszewska-Zaremba, Dorota; Gajewska, Alina; Misztal, Tomasz. (2025). Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS.. International journal of molecular sciences, 26(14). https://doi.org/10.3390/ijms26146570

Explore the wider topic